Arvinas logo
Close this search box.

An oral androgen receptor PROTAC® degrader for prostate cancer

Taavi K Neklesa, et al.

February 8, 2018
ASCO Genitourinary Cancers Symposium


You are now leaving Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

Skip to content